Drug Trial Radar · NCT06012721
Effect of Food on the Pharmacokinetics of ORIC-114
Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Sep 11, 2023
Primary completion
Nov 23, 2023
Study completion Nov 23, 2023
Sponsor
- Lead sponsor
- ORIC PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A randomized, 2-part, 2-sequence, 2-period, open-label, crossover study evaluating the effect of food on the pharmacokinetics (PK) of ORIC-114 tablet formulation in healthy adult subjects.
Conditions
- Food Effect in Healthy Participants
Interventions
ORIC-114Drug
Food effect healthy subjects
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration (Cmax)Time frame: 14 days
- Time of maximum observed concentration (Tmax)Time frame: 14 days
- Area under the curve (AUC)Time frame: 14 days
- Apparent plasma terminal elimination half-life (t1/2)Time frame: 14 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd., 235 Ryrie St
Geelong, Victoria, Australia
Nucleus Network Pty Ltd., Level 5, Burnet Tower, 89 Commercial Rd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.